Skip to main content
Premium Trial:

Request an Annual Quote

Incyte, Courting New Role as Drug Developer, Names New CEO, President, and CSO

SAN FRANCISCO, Nov. 26 - Incyte Genomics said on Monday that co-founder Roy Whitfield has been replaced as CEO by Paul Friedman, formerly the president of DuPont Pharmaceuticals Research Laboratories, in a move that underscores Incyte's intent to move swiftly from a genomics database provider to a profitable drug developer.


Incyte also has named president and chief scientific officer Robert Stein, a former executive vice president of research and preclinical development at DuPont Pharmaceuticals.


"Dr. Friedman and Dr. Stein are proven leaders who together created an impressive therapeutic pipeline at DuPont while building substantial value for DuPont's shareholders," said Whitfield, who will become Incyte's chairman. "Incyte's intellectual property portfolio provides them significant pharmaceutical opportunities to apply their leadership skills to expand the database and intellectual property licensing business and develop new medical therapeutics."


The management change follows on the heels of a broad corporate restructuring at Incyte, of Palo Alto, Calif., which includes shuttering the firm's custom genomics program and laying off roughly 400 employees. 


Incyte also announced that Friedman, Stein, and Julian Baker, a managing partner of Baker/Tisch Investments, have been elected to the copany's board of directors.

The Scan

Lung Cancer Response to Checkpoint Inhibitors Reflected in Circulating Tumor DNA

In non-small cell lung cancer patients, researchers find in JCO Precision Oncology that survival benefits after immune checkpoint blockade coincide with a dip in ctDNA levels.

Study Reviews Family, Provider Responses to Rapid Whole-Genome Sequencing Follow-up

Investigators identified in the European Journal of Human Genetics variable follow-up practices after rapid whole-genome sequencing.

BMI-Related Variants Show Age-Related Stability in UK Biobank Participants

Researchers followed body mass index variant stability with genomic structural equation modeling and genome-wide association studies of 40- to 72-year olds in PLOS Genetics.

Genome Sequences Reveal Range Mutations in Induced Pluripotent Stem Cells

Researchers in Nature Genetics detect somatic mutation variation across iPSCs generated from blood or skin fibroblast cell sources, along with selection for BCOR gene mutations.